Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Collaboration › Details

Galapagos–JPMorgan Chase: investor conference, 201901 supply service Galapagos presents at JP Morgan Healthcare Conference 2019

 

Period Period 2019-01-09
Region Region San Francisco, CA
  Country United States (USA)
Organisations Partner, 1st Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
  Partner, 2nd J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 37th Annual Healthcare Conference 2019 San Francisco
  Product 2 drug discovery services
Persons Person van de Stolpe, Onno (Galapagos 200501 CEO)
  Person 2 Goodwin, Elizabeth (Galapagos 201112 Director Investor Relations)
     

Galapagos N.V.. (12/21/18). "Press Release: Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference". Mechelen.

Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.

Onno van de Stolpe, CEO, will present on Wednesday, January 9 at 20:30 CET (11:30 a.m. Pacific time). The presentation will be live audio webcast and can be accessed via the following link: https://jpmorgan.metameetings.net/events/healthcare19/sessions/23994-galapagos-nv/webcast. A replay of the webcast will be available for 90 days on the Galapagos' website at www.glpg.com.


About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at glpg www.glpg.com.


Investors:

Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784

Sofie Van Gijsel
Director IR
+32 485 19 14 15
ir@glpg.com

Media:

Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com


Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

   
Record changed: 2019-03-14

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top